As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.
26 Analysts have issued a Revolution Medicines Inc forecast:
26 Analysts have issued a Revolution Medicines Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -526 -526 |
19%
19%
|
|
| EBIT (Operating Income) EBIT | -532 -532 |
19%
19%
|
|
| Net Profit | -500 -500 |
12%
12%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
| Head office | United States |
| CEO | Mark Goldsmith |
| Employees | 534 |
| Founded | 2004 |
| Website | www.revmed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


